Micron Biomedical
Micron Biomedical is a clinical-stage life science company and the leader in dissolvable microarray-based technology for needle-free delivery of vaccines and therapeutics. The company's mission is to radically expand access to treatments and vaccines, improve global health outcomes, and transform how vaccines and drugs are administered. Micron's proprietary technology enables painless, thermostable, and self-administered drug and vaccine delivery, eliminating the need for cold chain logistics and reducing infrastructure barriers. The company is recognized for its innovative approach to overcoming vaccine hesitancy and access challenges, and is rapidly advancing toward commercializing its technology for global impact. Micron partners with leading global health organizations and has secured significant funding to accelerate the development and commercialization of its needle-free solutions.
Micron Biomedical
What We Do
A proprietary, dissolvable microarray 'button' technology for needle-free, painless, and thermostable delivery of vaccines and therapeutics. Enables self-administration and reduces cold chain requirements.
A microarray patch-based, needle-free version of the measles-rubella vaccine, shown to be safe and immunogenic in children as young as 9 months. Supported by the Gates Foundation and recognized as a top innovation for global immunization.
A next-generation rotavirus vaccine delivered via dissolvable microarray patch, currently in first-in-human clinical trials in collaboration with Emory University and the CDC.
Development of a needle-free, microarray patch-delivered mRNA-based influenza vaccine in collaboration with Zipcode Bio, supported by a $2 million BARDA award.
A dissolving microneedle patch for long-acting contraception, delivering levonorgestrel for over a month with a single application. Licensed exclusively to Micron Biomedical.
Microneedle patch for inactivated rotavirus vaccine (IRV), developed in collaboration with the CDC for future clinical evaluation.
Infectious Diseases
Regenerative Medicine
Key People
EVP, Chief Technology Officer, Co-founder
EVP, Chief Financial Officer
EVP, Head of Technical Operations, Co-founder
Advisor
Scientific Advisor
News & Updates
Awarded $2 million by BARDA for collaboration with Zipcode Bio to develop mRNA-based broad protecting flu vaccine without needles.
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant
Received $3.7 million from CEPI to advance needle-free vaccine technology for rapid response to emerging diseases.
Secured $43 million in grant support, including from the Gates Foundation, to improve measles and rubella vaccine coverage and accelerate the world’s first phase 2 trial of needle-free technology in infants.
Finalist in the Prix Galien USA Award for breakthrough scientific innovation in the start-up category.
Received the Biotech Medical Innovation Award at Boston Biotech Week for advancing biopharmaceutical product and technology.
Recognized among leading biotechnology organizations at the ViE & WVCDC Awards.